oncology

Ipsen focuses on oncology to keep growing
Ipsen focuses on oncology to keep growing
GoInPharma
Ipsen
oncology
Xermelo
kidney cancer
Flag link:
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Ramping back up on oncology, GSK takes an option on Adaptimmune’s TCR cancer drug
Endpoints
GSK
oncology
Adaptimmune
TCR therapeutics
Flag link:
Jazz, ImmunoGen partner on hematology, oncology drug development
Jazz, ImmunoGen partner on hematology, oncology drug development
BioPharma Dive
Jazz Pharmaceuticals
Immunogen
oncology
hematology
drug development
Flag link:
New study of FDA cites the flaws behind rapid-fire cancer drug OKs
New study of FDA cites the flaws behind rapid-fire cancer drug OKs
Endpoints
FDA
drug approvals
cancer
oncology
Flag link:
Why Gilead Sciences Might Not Make an Oncology Acquisition
Why Gilead Sciences Might Not Make an Oncology Acquisition
Motley Fool
Gilead Sciences
M&A
oncology
Flag link:
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
A Cancer Conundrum: Too Many Drug Trials, Too Few Patients
NY Times, NY
cancer
oncology
clinical trials
patients
Flag link:
Intas Pharmaceuticals offered $1.5bn for 3 divisions of Teva’s in Europe
Intas Pharmaceuticals offered $1.5bn for 3 divisions of Teva’s in Europe
GoInPharma
Intas
India
M&A
Teva Pharmaceutical
Europe
Women's Health
oncology
pain management
Flag link:
Ending the era of $100,000 cancer drugs
Ending the era of $100,000 cancer drugs
Pharmafile
cancer
drug pricing
oncology
Flag link:
Teva sells as many as 4 assets: Medis, respiratory, women’s health and oncology
Teva sells as many as 4 assets: Medis, respiratory, women’s health and oncology
GoInPharma
Teva Pharmaceutical
M&A
Respiratory
Women's Health
oncology
Medis
Flag link:
Sanofi believes it’s still not too late to become a top player in cancer drug market
Sanofi believes it’s still not too late to become a top player in cancer drug market
Endpoints
Sanofi
oncology
R&D
Flag link:
Takeda partners to develop novel oncology therapies
Takeda partners to develop novel oncology therapies
Drug Delivery Business News
Takeda
Molecular Templates
Millenium
oncology
drug development
Flag link:
Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal
Bristol-Myers beefs up big cancer drug pipeline, buying IFM drugs in $2.3B-plus deal
Endpoints
Bristol-Myers Squibb
IFM Therapeutics
oncology
M&A
Flag link:
Lilly puts two-thirds of midphase cancer pipeline up for sale in major shake-up of R&D priorities
Lilly puts two-thirds of midphase cancer pipeline up for sale in major shake-up of R&D priorities
Fierce Biotech
Eli Lilly
M&A
oncology
R&D
Flag link:
How Reproducible are Preclinical Study Results?
How Reproducible are Preclinical Study Results?
Xtalks
preclinical study results
cancer
oncology
clinical trials
Flag link:
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Upstart women’s oncology company in-licenses PhII PARP; Beijing biotech grabs $29M startup round
Endpoints
oncology
PARP inhibitors
2X Oncology
Eisai
2X-121
Jazz Pharmaceuticals
Flag link:
Cancer's Big Infrastructure Problem
Cancer's Big Infrastructure Problem
Forbes
cancer
oncology
personalized medicine
clinical trials
clinical trial data
Flag link:
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us
Forbes
cancer
oncology
larotrectinib
Loxo Oncology
clinical trials
patients
Flag link:
Facts & Figures: Diversity in Oncology
Facts & Figures: Diversity in Oncology
ASCO.org
diversity
physicians
oncology
ASCO 2017
Flag link:
Why Novartis' Shah-Mehta chose a career in pharma sales
Why Novartis' Shah-Mehta chose a career in pharma sales
Medical Marketing and Media
Novartis
marketing
oncology
Flag link:
At big cancer meeting, a big question: Is the U.S. ‘losing its edge’
At big cancer meeting, a big question: Is the U.S. ‘losing its edge’
Stat
ASCO 2017
oncology
Flag link: